HLA Typing for Transplant Market Size By Technology (Non-Molecular Assays [Serological Assays, Mixed Lymphocyte Culture Assays], Molecular Assays [PCR Based Molecular Assays, Sequencing Based Molecular Assays {Sanger Sequencing, Next Generation Sequencing

HLA Typing for Transplant Market Size By Technology (Non-Molecular Assays [Serological Assays, Mixed Lymphocyte Culture Assays], Molecular Assays [PCR Based Molecular Assays, Sequencing Based Molecular Assays {Sanger Sequencing, Next Generation Sequencing}]), By Product and Services (Instruments, Reagents & Consumables, Software, Services), By Application (Diagnostics, Research), By End-use (Hospitals, Academic & Research Institutes), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028

The HLA typing for transplant market is estimated to register significant expansion by 2028 due to the expanding global geriatric population.

Studies have indicated that HLA (human leukocyte antigen) typing could be feasible to match umbilical cord blood (UCB) transplant recipient pairs in developing countries that have limited resources. Increasing prevalence of chronic diseases requiring organ transplantation has accelerated product adoption. In addition, recent technological advancements and R&D activities have augmented industry uptake over the past few years.

Notably, industry players have been implementing strategic initiatives to tap into emerging trends in the market, which has positively impacted overall business dynamics. For instance, in January 2022, Immucor, Inc., a leading provider of transplantation and transfusion services, launched its novel HLA typing software dubbed the MIA FORA NGS EXPRESS HLA Typing Software. The enhanced HLA typing software has been designed to include essential features, such as additional hardware and operating system support, shorter run-time, and a comprehensive summary page.

The HLA typing for transplant market has been segregated on the basis of end-use, technology, application, product and services, and region. From the technology perspective, the market has further been divided into molecular assays and non-molecular assays. The non-molecular assays sub-segment held a market share of nearly 16.5% in 2021 and is speculated to amass significant gains over the assessment period.

In terms of product and services, the HLA typing for transplant market has been classified into instruments, services, reagents and consumables, and software. In 2021, the services segment registered a valuation of around USD 93.4 million in 2021 and is expected to witness steady growth through the study timeline.

With respect to application, the market has been bifurcated into research and diagnostics. The HLA typing for transplant market from the research sub-segment is anticipated to reach a valuation of more than USD 241.7 million by the end of 2028.

Based on end-use, the HLA typing for translating market has been segmented into academic and research institutes, hospitals, and diagnostic labs. The diagnostic labs sub-segment is set to attain a notable share in the market by 2028, progressing at a growth rate of more than 8.1% over the review timeframe.

From the regional point of view, the Latin America HLA typing for transplant industry held above 6.8% market share in 2021 and is poised to gain substantial growth momentum over 2022-2028. Meanwhile, the Middle East & Africa HLA typing for transplant market is expected to garner a sizable revenue by 2028, developing at approximately 4.0% CAGR over the forecast period.